BioCapital Announces a Total of $7.6M Invested in Three Biotech Companies.MONTREAL--(BUSINESS WIRE)--June 3, 1999-- BIOCAPITAL (ME:BCK BCK Blue Crash Kit (webcomic) BCK Back-Country Kitchen BCK Bernstein, Cushner & Kimmell (law firm) BCK Brotherhood of the Crimson Knights (gaming clan) .UN.) (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :BCK.UN.) BioCapital Investments ("BioCapital") announces that it has completed a $7.6M investment in three companies active in the healthcare and biotechnology industry. These investments bring the total amount invested by BioCapital in healthcare and biotechnology companies up to $99M. $2.6M investment in Biovet Inc. - Biovet is a Quebec-based company which is engaged in the research and development, manufacturing and commercialization of novel veterinary diagnostic products and vaccines. Biovet has an extensive R&D program with renowned institutes in the field. Biovet has also assembled a portfolio of technologies from in-licensing and distribution agreements for diagnostic kits, porcine and bovine vaccines and artificial insemination devices and products that offer the control and elimination of diseases to animal food producers. This investment will accelerate the commercialization of its products on the U.S and European markets. $3M investment in AltaRex - Altarex is a publicly traded company publicly traded company A company whose shares of common stock are held by the public and are available for purchase by investors. The shares of publicly traded firms are bought and sold on the organized exchanges or in the over-the-counter market. (Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. : AXO AXO Asianxo (website) AXO Alpha Chi Omega (sorority) AXO Ach So AXO Access Extension Object ) focused on the research, development and commercialization of unique antibody-based therapeutics for the treatment of cancers. AltaRex has four products in various stages of development that have the potential to effectively treat seven of the top ten most lethal cancers. Its lead product, OvaRex(TM) MAb for ovarian cancer, is currently in Phase IIb clinical trials. Its second product, BrevaRex(TM) MAb for multiple myelome, is in Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I . This investment will help AltaRex fund its on-going research and development activities in Quebec. $2M investment in Synsorb - SYNSORB is a publicly-traded company (Toronto Stock Exchange: SYB a. 1. See Sib. ; NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : SYBB), developing orally delivered gastroenteric gas·tro·en·ter·ic adj. Relating to the gastrointestinal tract. gastroenteric pertaining to the stomach and intestines. products. The SYNSORB technology is based upon the role of carbohydrates in human biology. Its two lead products are comprised of carbohydrates bound to the surface of inert carriers. These carbohydrates show a specific affinity for toxins produced by bacteria in the GI tract during infection. The company lead product, SYNSORB Pk(R), is currently in Phase III clinical trials in Canada, the US, and Argentina for the treatment of E. coli 0157:H7 infections and the prevention of Hemolitic Uremic uremic pertaining to or emanating from uremia. uremic poisoning see uremia, visceral gout. uremic toxins Syndrome. Takeda Chemical Industries, Ltd., has an exclusive licensing agreement for the development and marketing of SYNSORB Pk(R) in Japan. PNSORB Pk(R) in Canada. The company second product, SYNSORB Cd(R), is currently in Phase II trials in Canada and the US. It is designed to bind the toxin associated with Clostridium difficile associated diarrhea. A library of compounds for viral and bacterial diarrhea in children as well as potential candidates for inflammatory conditions in gastroenterology are also being created and investigated. Synsorb has recently signed a collaboration agreement with Ocean Pharmaceuticals for the development of novel antibiotic therapies. This investment will increase Synsorb's research activities in Quebec. Profile BioCapital is a public investment fund that invests in healthcare and biotechnology companies with high growth potential. BioCapital features an innovative vehicle for investments in private and public companies, offering high diversification and significant liquidity. BioCapital distinguishes itself by the scientific and technological expertise of its management team and by the rigorous evaluation process of its investment opportunities. BioCapital is publicly traded on Montreal and Toronto stock exchanges (BCK.UN) and its net asset is $112M. On April 30, 1999, the net asset value per unit was $10.30. BioCapital's major partners include such outstanding investors as Fonds de solidarite des travailleurs du Quebec (F.T.Q.), Societe Innovatech du Grand Montreal, BioChem Pharma Inc., Royal Bank Capital Corporation, National Bank of Canada This article is about a commercial bank. For Canada's central bank, see Bank of Canada. National Bank of Canada (Banque Nationale du Canada) TSX: NA is the sixth largest bank in Canada, and so is one of the Big Six banks. and Banque de Vizille. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion